WILLIAM S. DUFFEY, JR., District Judge.
This matter is before the Court on the Commission's Motion to Dismiss [138] and the Commission's Motion for Imposition of Remedies [144].
This is a civil enforcement action brought by the Securities and Exchange Commission ("SEC" or the "Commission") under the Securities Exchange Act of 1934 ("Exchange Act") and the Investment Advisers Act of 1940 ("Advisers Act"). On October 19, 2010, the Commission filed its Complaint [1] against Defendants Paul T. Mannion, Jr. ("Mannion"), Andrew S. Reckles ("Reckles"), PEF Advisors Ltd. ("PEF Ltd."), and PEF Advisors LLC ("PEF LLC") (collectively, "Defendants"). The Complaint names Palisades Master Fund, L.P. (the "Palisades Fund" or the "Fund") as Relief Defendant. PEF Ltd. and PEF LLC are alleged to be the investment advisors to Palisades Equity Holdings Ltd. and Palisades Equity Fund, L.P., hedge funds that served as feeder funds for, and otherwise made investments through, the Palisades Fund. Mannion and Reckles are alleged to be the principals and co-owners of PEF Ltd. and PEF LLC.
In its Complaint, the Commission alleged various fraudulent schemes by Defendants, including that (i) in August, September, and October 2005, Defendants reported monthly "net asset values" ("NAVs") with inflated values of certain assets held by the Palisades Fund (the "Valuation Claim"), and (ii) in July and August 2005, Defendants personally exercised stock warrants, for shares of World Health Alternatives, Inc. ("World Health"), belonging to the Fund (the
On June 28, 2012, and July 30, 2012, the Commission and Defendants filed cross Motions for Summary Judgment [59, 66]. On March 25, 2013, the Court entered its Order [87], 2013 WL 1291621, on the motions (the "Summary Judgment Order"). With respect to the Valuation Claim, the Court found that the record lacked evidence of the amount of the alleged overvaluations stated in the September and October 2005 NAVs. On this basis, the Court concluded that the trier of fact could not determine the amount by which the overvaluations inflated Defendants' management fees and could not, therefore, determine whether the overvaluations were "material" under Section 206. The Court thus granted Defendants summary judgment on the Valuation Claim asserted under Section 206 based on the September and October 2005 NAVs. The Court further found that, with respect to the August 2005 NAV, the record contained sufficient evidence of "materiality" to allow the Section 206 claims based on the August 2005 NAV to proceed to trial.
With respect to the Misappropriation Claim, the Court found that the record established Defendants' liability under Section 206(2), and the Court granted the Commission summary judgment on its Section 206(2) Misappropriation Claim. The Court found that the record showed a genuine dispute as to whether Defendants acted with scienter under Sections 10(b) and 206(1). The Court thus denied summary judgment to both the Commission and Defendants on the Misappropriation Claim asserted under Sections 10(b) and 206(1).
On April 22, 2013, the Commission filed its Motion for Reconsideration [89] of the Court's Summary Judgment Order. With respect to the Misappropriation Claim, the Commission argued, as it did in its Motion for Summary Judgment, that the record establishes as a matter of law that Defendants acted with scienter in exercising the Palisades Fund's warrants. In its Order on the Motion for Reconsideration [136] (the "Reconsideration Order"), the Court again found that the facts supporting scienter are in dispute and are required to be decided by the finder of fact at trial.
Following the Court's Reconsideration Order, the following claims remained to be tried in this matter: (i) that Defendants violated Section 206 of the Advisers Act by overvaluing the August 2005 NAV (the "Section 206 Valuation Claim"); (ii) that Defendants violated Section 10(b) of the Exchange Act by misappropriating the Fund's World Health warrants (the "Section 10(b) Misappropriation Claim"); and (iii) that Defendants violated Section 206(1) of the Advisers Act by misappropriating the Fund's World Health warrants (the "Section 206(1) Misappropriation Claim").
On March 12, 2014, the Commission filed its Motion to Dismiss seeking to voluntarily dismiss with prejudice, under Rule 41(a) of the Federal Rules of Civil Procedure, all of its claims remaining to be tried, including the Section 206 Valuation Claim, the Section 10(b) Misappropriation Claim, and the Section 206(1) Misappropriation Claim. Defendants consented to the Motion to Dismiss.
On May 19, 2014, the Commission filed its Motion for Imposition of Remedies related to its Section 206(2) Misappropriation Claim, on which the Court previously granted summary judgment in the Commission's favor. The Commission seeks disgorgement of Defendants' gains from their exercise of the Palisades Fund's World Health warrants, a permanent injunction prohibiting Defendants from violating the Advisers Act, and a civil penalty.
In its Motion to Dismiss, the Commission seeks, under Rule 41(a) of the Federal Rules of Civil Procedure, the voluntary dismissal with prejudice of its Section 206 Valuation Claim, Section 10(b) Misappropriation Claim, and Section 206(1) Misappropriation Claim. Courts uniformly have held that Rule 41(a) does not permit the dismissal of individual claims from a multi-claim action but only authorizes the dismissal of an entire action. See 9 Charles Alan Wright & Arthur R. Miller, Federal Practice and Procedure § 2362, at 413-14 & n. 13 (3d ed. 2008 & Supp.2012) (collecting cases) ("Rule 41(a) is applicable only to the voluntary dismissal of all the claims in an action."); see also Klay v. United Healthgroup, Inc., 376 F.3d 1092, 1106 (11th Cir.2004) (holding that a district court is "not empowered to dismiss only certain claims under Rule 41"); Exxon Corp. v. Md. Cas. Co., 599 F.2d 659, 662 (5th Cir.1979)
The Court cannot grant a voluntary dismissal, under Rule 41(a), of the claims the Commission seeks to dismiss because those claims do not constitute the Commission's entire action. See Fed.R.Civ.P. 41(a)(1)(A); Klay, 376 F.3d at 1106. The Court, however, construes the Motion to Dismiss as an unopposed motion, under Rule 15, to amend Plaintiffs' Complaint to remove the Section 206 Valuation Claim, the Section 10(b) Misappropriation Claim, and the Section 206(1) Misappropriation Claim. See, e.g., Anderberg v. Masonite Corp., 176 F.R.D. 682, 686 (N.D.Ga.1997) ("When a party seeks to dismiss a single claim in a multi-count complaint instead of an entire action, ... the motion should be treated as a motion to amend the complaint under Rule 15(a) to delete the specific claim."). Because the parties consent to the removal of these claims, the Court grants the motion to dismiss under Rule 15(a). See Fed.R.Civ.P. 15(a)(2) (providing that "a party may amend its pleading ... with the opposing party's written consent").
District courts possess general equitable powers to remedy violations of the
A defendant who violates the securities laws, including the Advisers Act, is generally liable for disgorgement of "ill-gotten gains." See, e.g., SEC v. Calvo, 378 F.3d 1211, 1217 (11th Cir.2004); see also SEC v. Lauer, 478 Fed.Appx. 550, 557 (11th Cir.2012). "The remedy of disgorgement is designed both to deprive a wrongdoer of his unjust enrichment and to deter others from violating the securities laws. `The purpose of disgorgement is not to compensate the victims of the fraud, but to deprive the wrongdoer of his ill-gotten gain.'" SEC v. Phoenix Telecom, L.L.C., 231 F.Supp.2d 1223, 1225 (N.D.Ga.2001) (citation omitted) (quoting SEC v. Blatt, 583 F.2d 1325, 1335 (5th Cir.1978)).
"The SEC is entitled to disgorgement upon producing a reasonable approximation of a defendant's ill-gotten gains." Calvo, 378 F.3d at 1217 (citing SEC v. Warde, 151 F.3d 42, 50 (2d Cir.1998); SEC v. First Pac. Bancorp., 142 F.3d 1186, 1192 n. 6 (9th Cir.1998); SEC v. First City Fin. Corp., 890 F.2d 1215, 1231-32 (D.C.Cir. 1989)). "The burden then shifts to the defendant to demonstrate that the SEC's estimate is not a reasonable approximation." Id. (citing First City, 890 F.2d at 1232). "Exactitude is not a requirement; `[s]o long as the measure of disgorgement is reasonable, any risk of uncertainty should fall on the wrongdoer whose illegal conduct created that uncertainty.'" Id. (quoting Warde, 151 F.3d at 50).
In this case, the Court found that Defendants violated Section 206(2) of the Advisers Act when they personally exercised the World Health warrants belonging to their client, the Palisades Fund. Using the Palisades Fund's warrants, Defendants purchased, for $1.90 per share, 1,044,396 shares of World Health stock. The market price of World Health stock at the time of the transaction was $3.55 per share. Defendants thus purchased, for $1,984,352.40, stock with a market value of $3,707,605.80. The Commission argues that Defendants' ill-gotten gain in exercising their client's warrants is the difference between the purchase and market prices of the stock, which is $1,723,253.40.
Defendants assert that the Commission's calculation is not appropriate because Defendants did not sell their World Health stock for $3.55 per share and never realized the gains asserted. Defendants contend that World Health's share price dropped precipitously following Defendants' exercise of the warrants, and Defendants ultimately lost over $1.6 million from the transaction. Defendants thus argue that they do not have any ill-gotten gains to disgorge.
Although the Eleventh Circuit has not directly considered the effect of a post-transaction decline in value, on the determination of a disgorgement amount, every circuit that has addressed the issue has held that disgorgement is properly based
Defendants next argue that the Commission's valuation method — subtracting the warrant purchase price of the World Health shares from the market price of the shares — is not proper. Defendants assert that they liable for misappropriating warrants — the right to buy stock at a determined price. Defendants argue that expert testimony is required to assign a value to this warrant right. Defendants' argument ignores the fact that Defendants did not simply take the warrants, but they exercised them. In this case, the value of the warrants is not theoretical, or based on the possibility of future exercise. Expert testimony is not necessary. Cf. Centel Commc'ns Co. v. Comm'r, 920 F.2d 1335, 1338 (7th Cir.1990) (holding that, for tax purposes, the value of warrants becomes known upon their exercise). The Court finds that the ill-gotten gains in this case can be reasonably approximated based on the difference between the purchase and market prices of the World Health shares that were the subject of the warrants.
Defendants next argue that the amount of the disgorgement should be reduced by: (i) 22%, because Defendants themselves owned 22% of the Palisades Fund, and (ii) the amount they already refunded to the Palisades Fund after selling the World Health shares at issue. The Commission did not dispute, or otherwise respond to, Defendants' argument that they are entitled to a 22% reduction, and the Court finds that a 22% reduction in the total amount disgorgement is appropriate.
Although the Commission does not dispute that Defendants would be entitled to a reduction based on any refunds paid, the Commission disputes that Defendants actually re-paid to the Fund any proceeds from the sale of Defendants' World Health shares.
The final amount of disgorgement will equal 78% of the amount remaining after
The Advisers Act provides that a defendant shown to have violated the Act is liable for an injunction against future violations. See 15 U.S.C. § 80b-9(d). The Eleventh Circuit has held that the Commission is entitled to an injunction when it establishes "(1) a prima facie case of previous violations of federal securities laws, and (2) a reasonable likelihood that the wrong will be repeated." SEC v. Unique Fin. Concepts, Inc., 196 F.3d 1195, 1199 n. 2 (11th Cir.1999) (citing SEC v. Mgmt. Dynamics, Inc., 515 F.2d 801, 806-07 (2d Cir.1975); SEC v. Manor Nursing Ctrs., Inc., 458 F.2d 1082, 1100 (2d Cir.1972)). The Court has found that Defendants violated Section 206(2) of the Advisers Act, and the first element for injunctive relief is thus satisfied. The parties dispute whether there is evidence of "a reasonable likelihood that the wrong will be repeated."
In evaluating the likelihood of recurrence, the Court considers several factors, including:
SEC v. Carriba Air, Inc., 681 F.2d 1318, 1322 (11th Cir.1982) (quoting Blatt, 583 F.2d at 1334 n. 29). Of these factors, only one is undisputed: Defendants continue to work in the investment industry.
Regarding whether Defendants' violation was "isolated or recurrent," the Commission argues that Defendants should be deemed repeat offenders because of other alleged violations, including (i) allegations of violations arising out of the same facts giving rise to this action, including the Valuation Claim, and (ii) prior, unrelated regulatory arbitrations regarding Defendants' conduct. With respect to the Valuation Claim and other alleged violations related to this action, the Court previously
The remaining factors governing injunctive relief also are in dispute. The "egregiousness" of Defendants' conduct turns largely on whether Defendants acted with scienter. As the Court discussed fully in its Summary Judgment Order and its Reconsideration Order, scienter is disputed and can be resolved only by a finder of fact.
Whether to enter an injunction in this matter depends on the resolution of certain factual disputes: the relevance of prior regulatory arbitrations against Defendants, whether Defendants acted with scienter, whether Defendants have given "sincere" assurances against future violations, and whether Defendants recognize their wrongful conduct. The Court will consider these limited disputes at an evidentiary hearing.
The Court may impose penalties for violations of the Advisers Act as follows:
15 U.S.C. § 80b-9(e)(2).
Defendants concede that they are liable for a "first tier" penalty. The Commission argues that the Court should impose a "second" or "third tier" penalty. The imposition of a penalty above the "first tier" requires a showing that Defendants' conduct "involved fraud, deceit, manipulation, or deliberate or reckless disregard of a regulatory requirement." Id. In other words, a "second" or "third tier" penalty requires a showing of scienter. As discussed above, the issue of scienter is required to be decided by a finder of fact at an evidentiary hearing. The Court will determine the appropriate amount of a civil penalty after the hearing.
Accordingly, for the foregoing reasons,